$CDXS

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

U.S. stocks were mixed mid-session. Verizon (NYSE:VZ) reported Q2 adjusted EPS of $1.30 vs $1.27 consensus, with revenue of $34.25B missing the $35.11B estimate. GAAP EPS fell to 92 cents. Verizon raised full-year adjusted EPS guidance to $4.99-$5.04. Oil fell 4.3% to $88.26.

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001200375 0001200375 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,

Analysts have re-evaluated Codexis, Inc. (CDXS) after its latest quarterly results, which showed stronger-than-expected revenues of US$15m and lower losses per share at US$0.10. Despite an improved sentiment regarding future losses, the consensus price target has been reduced by 7.1% to US$6.58 due to ongoing profitability concerns and an anticipated revenue decline of 5.0% in 2026, contrasting with industry growth.

Codexis (NASDAQ: CDXS) has announced an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its ECO Synthesis platform for a partner's preclinical cardiovascular program. This agreement demonstrates the platform's ability to produce material beyond early research volumes and serves as a potential pathway to further scale-up and commercial manufacturing. While no financial terms were disclosed, the deal highlights Codexis's ongoing efforts to commercialize its ECO Synthesis platform for larger-scale RNA therapeutics.

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

REDWOOD CITY, Calif., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Codexis, Inc. ( NASDAQ: CDXS ) , a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing ...

Codexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?